Certara

Blog

FAQs: The ICH M15 Guideline and What It Means for Model-Informed Drug Development

Learn what the ICH M15 guideline means for Model-Informed Drug Development, regulatory credibility, harmonization, and…

CertaraFebruary 18, 2026

On-Demand Webinar

Accelerate Decisions with Certara IQ™: Scalable, AI-Driven QSP for Drug Development

Discover how Certara's AI-powered QSP modeling software, Certara IQ is overcoming challenges in drug development…

CertaraFebruary 17, 2026

Guide

Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD)

Prepare for ICH M15 guideline: Learn how to assess model credibility, align terminology, and strengthen…

CertaraFebruary 13, 2026

On-Demand Webinar

Simcyp® Simulator Version 25: Streamline Drug Development with Regulatory-Compliant PBPK

JTVCdGVhbV9tZW1iZXJzJTVESenior Principal ScientistAssociate Principal ScientistPrincipal ScientistSenior Research ScientistDiscover real-world success stories where sponsors leveraged Simcyp…

CertaraFebruary 12, 2026

Guide

EMA Policy 0070 Submission Readiness Checklist

Use this EMA Policy 0070 Submission Checklist to prepare compliant clinical data packages, manage anonymization…

CertaraFebruary 12, 2026

On-Demand Webinar

The “Easy Button” for PK/PD TFLs and Reports (TFL Studio & AI PK Reports)

Watch to see how Phoenix TFL Studio and AI PK Reports automate the final stages…

CertaraFebruary 12, 2026

Live Events

Certara IQ^™ Global Roadshow

Certara IQ™ is going on the road. From APAC to Europe to North America, our…

CertaraFebruary 12, 2026

Live Events

Certara IQ™ Workshop

CertaraFebruary 11, 2026

Publication

Anti-PD-(L)1 Antibodies: Insights From QSP-Based Meta-Analysis

Anti-PD-1 and anti-PD-L1 antibodies have transformed cancer immunotherapy, yet clinical meta-analyses suggest differences in efficacy…

CertaraFebruary 11, 2026

Blog

Pediatric Drug Development: From “Wild West” to Model-Informed Confidence

Model-informed drug development and precision dosing are transforming pediatric programs, from regulatory planning to Bayesian…

CertaraFebruary 11, 2026

FAQs: The ICH M15 Guideline and What It Means for Model-Informed Drug Development

Accelerate Decisions with Certara IQ™: Scalable, AI-Driven QSP for Drug Development

Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD)

Simcyp® Simulator Version 25: Streamline Drug Development with Regulatory-Compliant PBPK

EMA Policy 0070 Submission Readiness Checklist

The “Easy Button” for PK/PD TFLs and Reports (TFL Studio & AI PK Reports)

Certara IQ^™ Global Roadshow

Certara IQ™ Workshop

Anti-PD-(L)1 Antibodies: Insights From QSP-Based Meta-Analysis

Pediatric Drug Development: From “Wild West” to Model-Informed Confidence

Newsletter sign up

Quick links

Solutions

Contact